Drug intelligence / Profile preview

AFYX-004

Development stage: Unknown
Lead developer: AFYX Therapeutics
Modality: Small Molecules
Administration: Intranasal

Overview

AFYX-004 is a small molecule nasal spray formulation being developed by AFYX Therapeutics for the treatment of cluster headache. It acts by modulating the N-methyl-D-aspartate (NMDA) receptor. The drug is currently in Phase 2 clinical development, aiming to provide acute relief for cluster headache patients through a non-invasive intranasal route of administration. By targeting the NMDA receptor, AFYX-004 seeks to address the underlying pathophysiology of cluster headache attacks, which are characterized by severe, debilitating pain.

Targets

HTR1B (5-Hydroxytryptamine Receptor 1B)PTGER4 (Prostaglandin E2 receptor EP4 subtype)NMDAR (Glutamate receptor ionotropic, NMDA)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on AFYX-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFYX-004.

Explore the full profile